Creating a new vaccine to trigger strong immune responses against HIV
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies
This study is exploring a new way to help the immune system fight HIV by creating a special vaccine that encourages the body to produce strong antibodies, and it's being tested in monkeys to find the best approach for developing a vaccine for people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11098607 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunogen derived from HIV-1 that aims to stimulate the immune system to produce broadly neutralizing antibodies (bNAbs). By studying the coevolution of antibodies and viral proteins in animal models, the researchers aim to understand how to effectively prime and enhance the immune response against HIV. The approach involves using simian-human immunodeficiency viruses (SHIVs) in rhesus macaques to identify patterns that can inform vaccine design for humans. The ultimate goal is to create a vaccine that can provide better protection against HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV infection who may benefit from enhanced immunization strategies.
Not a fit: Patients who are already living with HIV or those who are not at risk for HIV infection may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that significantly improves immune protection for individuals at risk of HIV infection.
How similar studies have performed: Previous research has shown promising results in using similar immunogen designs to elicit immune responses, indicating potential for success in this novel approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Shaw, George M — University of Pennsylvania
- Study coordinator: Shaw, George M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.